Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.

Inclusion Criteria: * Sex: male or female * Age: from 18 to 80 years * Histology: gastric cancer * Clinical stage: stage IV * Karnofsky performance status: more than 50% * Expected survival: more than 2 months * Laboratory tests results 7 days before the start of treatment: * White blood cells: more than 3.0 × 109/L * Platelets: more than 100 × 109/L * Neutrophils: more than 1.5 × 109/L * Hemoglobin: more than 80g/L * Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN) * Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN * Serum bilirubin: less than 1.25 × ULN * Serum creatinine: less than 1.25 × ULN * Pregnancy test: the test of women of child-bearing period must be negative 7 days before the start of treatment * Contraception: male and female subjects of child-bearing period must adopt a reliable method of contraception before entry into this study until 30 days after stopping this study * Informed consent: subject must have the ability to understand and voluntarily sign a written informed consent Exclusion Criteria: * History of neoplasms: other neoplasms * Medical history: mental disease, or congestive heart failure, or severe coronary artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy * Metastasis: clinical symptoms of brain metastasis * Other clinical trial: the subject received other clinical trial before this study * Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus was positive * Woman: pregnant or lactating women * Compliance: poor compliance